BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 28728165)

  • 1. Active multiple myeloma suppresses and typically eliminates coexisting MGUS.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Br J Cancer; 2017 Sep; 117(6):835-839. PubMed ID: 28728165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and outcomes in biclonal gammopathies.
    Mullikin TC; Rajkumar SV; Dispenzieri A; Buadi FK; Lacy MQ; Lin Y; Dingli D; Go RS; Hayman SR; Zeldenrust SR; Russell SJ; Lust JA; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
    Am J Hematol; 2016 May; 91(5):473-5. PubMed ID: 26840395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for M-proteinemia consisting of monoclonal gammopathy of undetermined significance and multiple myeloma for 30 years among atomic bomb survivors in Hiroshima.
    Fujimura K; Sugiyama A; Akita T; Ohisa M; Nagashima S; Katayama K; Maeda R; Tanaka J
    Int J Hematol; 2021 Apr; 113(4):576-585. PubMed ID: 33389658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients.
    Bosseboeuf A; Seillier C; Mennesson N; Allain-Maillet S; Fourny M; Tallet A; Piver E; Lehours P; Mégraud F; Berthelot L; Harb J; Bigot-Corbel E; Hermouet S
    Front Immunol; 2020; 11():854. PubMed ID: 32536913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Unexpected symptoms of monoclonal gammopathy].
    Smit PM; Abrahams AC; Schutgens RGE; Notermans NC; Minnema MC
    Ned Tijdschr Geneeskd; 2017; 161():D1741. PubMed ID: 29027517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.
    Landgren O; Kyle RA; Pfeiffer RM; Katzmann JA; Caporaso NE; Hayes RB; Dispenzieri A; Kumar S; Clark RJ; Baris D; Hoover R; Rajkumar SV
    Blood; 2009 May; 113(22):5412-7. PubMed ID: 19179464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
    Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
    Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
    Zingone A; Kuehl WM
    Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance.
    O'Sullivan LR; Meade-Murphy G; Gilligan OM; Mykytiv V; Young PW; Cahill MR
    Br J Haematol; 2021 Jan; 192(2):322-332. PubMed ID: 32478420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
    Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
    Stelmach-Gołdyś A; Czarkowska-Paczek B
    Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.
    Landgren O; Zeig-Owens R; Giricz O; Goldfarb D; Murata K; Thoren K; Ramanathan L; Hultcrantz M; Dogan A; Nwankwo G; Steidl U; Pradhan K; Hall CB; Cohen HW; Jaber N; Schwartz T; Crowley L; Crane M; Irby S; Webber MP; Verma A; Prezant DJ
    JAMA Oncol; 2018 Jun; 4(6):821-827. PubMed ID: 29710195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience.
    Alfano G; Fontana F; Colaci E; Messerotti A; Bettelli F; Potenza L; Luppi M; Cappelli G
    Transplantation; 2017 Nov; 101(11):e337-e342. PubMed ID: 28731904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
    Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
    Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
    Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
    Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
    Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
    Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.